Shell Asset Management CO Biocryst Pharmaceuticals Inc Transaction History
Shell Asset Management CO
- $2.2 Billion
- Q1 2024
A detailed history of Shell Asset Management CO transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Shell Asset Management CO holds 20,557 shares of BCRX stock, worth $173,295. This represents 0.01% of its overall portfolio holdings.
Number of Shares
20,557
Previous 21,854
5.93%
Holding current value
$173,295
Previous $111,000
14.41%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
257Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$168 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$158 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$106 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$78.8 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$74.4 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.57B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...